RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC

Ovarian cancer is the leading cause of gynecologic cancer-related death, and PARP inhibitors (PARPis) are becoming a promising treatment option, as demonstrated by recent clinical trials. After PARPi exposure, somatic reversion mutations in the homologous recombination genes may be a mechanism of PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jing, Dai, Yilin, Gao, Yi, Chai, Ranran, Lu, Chong, Yu, Bing, Kang, Yu, Xu, Congjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572335/
https://www.ncbi.nlm.nih.gov/pubmed/37833926
http://dx.doi.org/10.3390/ijms241914476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572335/
https://www.ncbi.nlm.nih.gov/pubmed/37833926
http://dx.doi.org/10.3390/ijms241914476

Ejemplares similares